Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Current Scenario and Future Prospect in the Management of COVID-19

Author(s): Pobitra Borah, Pran Kishore Deb*, Satyendra Deka, Katharigatta N. Venugopala, Vinayak Singh, Raghu Prasad Mailavaram, Kiran Kalia and Rakesh Kumar Tekade*

Volume 28, Issue 2, 2021

Published on: 08 September, 2020

Page: [284 - 307] Pages: 24

DOI: 10.2174/0929867327666200908113642

Price: $65

Abstract

The COVID-19 pandemic continues to wreak havoc worldwide due to the lack of risk assessment, rapid spreading ability, and propensity to precipitate severe disease in comorbid conditions. In an attempt to fulfill the demand for prophylactic and treatment measures to intercept the ongoing outbreak, the drug development process is facing several obstacles and renaissance in clinical trials, including vaccines, antivirals, immunomodulators, plasma therapy, and traditional medicines. This review outlines the overview of SARS-CoV-2 infection, significant recent findings, and ongoing clinical trials concerning current and future therapeutic interventions for the management of advancing pandemic of the century.

Keywords: COVID-19, SARS-CoV-2, Cytokine Storm, Remdesivir, TCM, Convalescent Plasma, Vaccines.

« Previous Next »
[1]
World Health Organization Coronavirus Disease (COVID-19) - events as they happen . https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen (Accessed date: Jul 2, 2020).
[2]
Jin, Y.; Yang, H.; Ji, W.; Wu, W.; Chen, S.; Zhang, W.; Duan, G. virology, epidemiology, pathogenesis, and control of COVID-19. Viruses, 2020, 12(4), 372.
[http://dx.doi.org/10.3390/v12040372] [PMID: 32230900]
[3]
Guo, Y-R.; Cao, Q-D.; Hong, Z-S.; Tan, Y-Y.; Chen, S-D.; Jin, H-J.; Tan, K-S.; Wang, D-Y.; Yan, Y. The Origin, Transmission and clinical therapies on coronavirus disease 2019 (COVID-19) Outbreak-an Update on the Status. Mil. Med. Res., 2020, 7(1), 1-10.
[http://dx.doi.org/10.1186/s40779-020-00240-0] [PMID: 31928528]
[4]
Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N.G.; Decroly, E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res., 2020, 176104742
[http://dx.doi.org/10.1016/j.antiviral.2020.104742] [PMID: 32057769]
[5]
Tang, X.; Wu, C.; Li, X.; Song, Y.; Yao, X.; Wu, X.; Duan, Y.; Zhang, H.; Wang, Y.; Qian, Z. On the origin and continuing evolution of SARS-CoV-2. Natl. Sci. Rev., 2020.
[http://dx.doi.org/10.1093/nsr/nwaa036]
[6]
Technical guidance. Avaialble at : . https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance(Accessed date: Jul 2, 2020)
[7]
Worldometer. Avaialble at : . https://www.worldometers. info/coronavirus/(Accessed date: Aug 11, 2020).
[8]
Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223), 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[9]
Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; Zhao, Y.; Li, Y.; Wang, X.; Peng, Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, 323(11), 1061-1069.
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[10]
Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.S.C.; Du, B.; Li, L.J.; Zeng, G.; Yuen, K.Y.; Chen, R.C.; Tang, C.L.; Wang, T.; Chen, P.Y.; Xiang, J.; Li, S.Y.; Wang, J.L.; Liang, Z.J.; Peng, Y.X.; Wei, L.; Liu, Y.; Hu, Y.H.; Peng, P.; Wang, J.M.; Liu, J.Y.; Chen, Z.; Li, G.; Zheng, Z.J.; Qiu, S.Q.; Luo, J.; Ye, C.J.; Zhu, S.Y.; Zhong, N.S. China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med., 2020, 382(18), 1708-1720.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[11]
Lundstrom, K. Coronavirus pandemic-therapy and vaccines. Biomedicines, 2020, 8(5), 109.
[http://dx.doi.org/10.3390/biomedicines8050109] [PMID: 32375268]
[12]
Hasöksüz, M.; Kiliç, S.; Saraç, F. Coronaviruses and SARS-COV-2. Turk. J. Med. Sci., 2020, 50(SI-1), 549-556.
[http://dx.doi.org/10.3906/sag-2004-127] [PMID: 32293832]
[13]
Malik, Y.A. Properties of coronavirus and SARS-CoV-2. Malays. J. Pathol., 2020, 42(1), 3-11.
[PMID: 32342926]
[14]
Alanagreh, L.; Alzoughool, F.; Atoum, M. The human coronavirus disease COVID-19: Its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens, 2020, 9(5), 331.
[http://dx.doi.org/10.3390/pathogens9050331] [PMID: 32365466]
[15]
Hamming, I.; Timens, W.; Bulthuis, M.L.C.; Lely, A.T.; Navis, G.; van Goor, H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol., 2004, 203(2), 631-637.
[http://dx.doi.org/10.1002/path.1570] [PMID: 15141377]
[16]
Yu, F.; Du, L.; Ojcius, D. M.; Pan, C.; Jiang, S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China Microbes Infect. 2020.
[http://dx.doi.org/10.1016/j.micinf.2020.01.003]
[17]
Belouzard, S.; Chu, V.C.; Whittaker, G.R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. USA, 2009, 106(14), 5871-5876.
[http://dx.doi.org/10.1073/pnas.0809524106] [PMID: 19321428]
[18]
Ashour, H.M.; Elkhatib, W.F.; Rahman, M.M.; Elshabrawy, H.A. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathogens, 2020, 9(3), 186.
[http://dx.doi.org/10.3390/pathogens9030186] [PMID: 32143502]
[19]
Ahn, D-G.; Shin, H-J.; Kim, M.H.; Lee, S.; Kim, H-S.; Myoung, J.; Kim, B-T.; Kim, S-J. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J. Microbiol. Biotechnol., 2020, 30(3), 313-324.
[http://dx.doi.org/10.4014/jmb.2003.03011] [PMID: 32238757]
[20]
Tay, M.Z.; Poh, C.M.; Rénia, L.; MacAry, P.A.; Ng, L.F.P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol., 2020, 20(6), 363-374.
[http://dx.doi.org/10.1038/s41577-020-0311-8] [PMID: 32346093]
[21]
Yang, M. Cell pyroptosis, a potential pathogenic mechanism of 2019-NCoV infection, 2020.
[http://dx.doi.org/10.2139/ssrn.3527420]
[22]
Tian, S.; Hu, W.; Niu, L.; Liu, H.; Xu, H.; Xiao, S-Y. pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J. Thorac. Oncol., 2020, 15(5), 700-704.
[http://dx.doi.org/10.1016/j.jtho.2020.02.010] [PMID: 32114094]
[23]
Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J. clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med., 2020, 46, 846-848.
[http://dx.doi.org/10.1007/s00134-020-05991-x] [PMID: 32253449]
[24]
World Health Organization; Clinical management of COVID-19., Available at: . https://www.who.int/publications-detail/clinical-management-of-covid-19 (Accessed date Jul 2, 2020.).
[25]
Worldometer Coronavirus Incubation Period (COVID-19).. https://www.worldometers.info/coronavirus/coronavirus-incubation-period/(Accessed date Jul 2, 2020)
[26]
Kang, Y.; Xu, S. Comprehensive overview of COVID-19 based on current evidence. Dermatol. Ther. (Heidelb.), 2020.e13525
[http://dx.doi.org/10.1111/dth.13525] [PMID: 32378801]
[27]
Jin, Y-H.; Cai, L.; Cheng, Z-S.; Cheng, H.; Deng, T.; Fan, Y-P.; Fang, C.; Huang, D.; Huang, L-Q.; Huang, Q.; Han, Y.; Hu, B.; Hu, F.; Li, B.H.; Li, Y.R.; Liang, K.; Lin, L.K.; Luo, L.S.; Ma, J.; Ma, L.L.; Peng, Z.Y.; Pan, Y.B.; Pan, Z.Y.; Ren, X.Q.; Sun, H.M.; Wang, Y.; Wang, Y.Y.; Weng, H.; Wei, C.J.; Wu, D.F.; Xia, J.; Xiong, Y.; Xu, H.B.; Yao, X.M.; Yuan, Y.F.; Ye, T.S.; Zhang, X.C.; Zhang, Y.W.; Zhang, Y.G.; Zhang, H.M.; Zhao, Y.; Zhao, M.J.; Zi, H.; Zeng, X.T.; Wang, Y.Y.; Wang, X.H. for the Zhongnan Hospital of Wuhan university novel coronavirus management and research team; evidence-based medicine chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil. Med. Res., 2020, 7(1), 4.
[http://dx.doi.org/10.1186/s40779-020-0233-6] [PMID: 32029004]
[28]
Li, H.; Liu, Z.; Ge, J. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. J. Cell. Mol. Med., 2020, 24(12), 6558-6570.
[http://dx.doi.org/10.1111/jcmm.15364] [PMID: 32320516]
[29]
Epidemiology, C.P.E.R. Epidemiology Working Group for NCIP Epidemic Response, Chinese center for disease control and prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi, 2020, 41(2), 145-151.
[http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003] [PMID: 32064853]
[30]
Zhao, J.; Yang, Y.; Huang, H.-P.; Li, D.; Gu, D.-F.; Lu, X.-F.; Zhang, Z.; Liu, L.; Liu, T.; Liu, Y.-K. Relationship between the ABO Blood Group and the COVID-19 Susceptibility medRxiv, 2020.
[http://dx.doi.org/10.1101/2020.03.11.20031096]
[31]
Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, 395(10223), 507-513.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[32]
National Institutes of Health. Coronavirus Disease 2019 (COVID-19); Treatment Guidelines, 2020.
[33]
Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395(10229), 1054-1062.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[34]
Wang, M.; Wu, Q.; Xu, W.; Qiao, B.; Wang, J.; Zheng, H.; Jiang, S.; Mei, J.; Wu, Z.; Deng, Y. Clinical diagnosis of 8274 samples with 2019-Novel Coronavirus in Wuhan medRxiv. 2020.
[http://dx.doi.org/10.1101/2020.02.12.20022327]
[35]
Helmy, Y.A.; Fawzy, M.; Elaswad, A.; Sobieh, A.; Kenney, S.P.; Shehata, A.A. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment and control. J. Clin. Med., 2020, 9(4), 1225.
[http://dx.doi.org/10.3390/jcm9041225] [PMID: 32344679]
[36]
Chan, J.F-W.; Kok, K-H.; Zhu, Z.; Chu, H.; To, K.K-W.; Yuan, S.; Yuen, K-Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect., 2020, 9(1), 221-236.
[http://dx.doi.org/10.1080/22221751.2020.1719902] [PMID: 31987001]
[37]
World Health Organization; Laboratory Testing for Coronavirus Disease 2019 (COVID-19) in Suspected Human Cases. Interim Guidance March 2020., 2020, Available at:; https://apps.who.int/iris/bitstream/handle/10665/31329/WHO-COVID-19-laboratory-2020.4-eng.pdf (Accessed date: July, 2020).2, 2020.[Available at.
[38]
Center for Devices and Radiological Health. Emergency Use Authorizations; FDA, 2020.
[39]
Ozma, M.A.; Maroufi, P.; Khodadadi, E.; Köse, Ş.; Esposito, I.; Ganbarov, K.; Dao, S.; Esposito, S.; Dal, T. Zeinalzadeh, E.; Kafil, H.S. Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period. Infez. Med., 2020, 28(2), 153-165.
[PMID: 32275257]
[40]
Center for Devices and Radiological Health. EUA Authorized Serology Test Performance; FDA, 2020.
[41]
Yang, W.; Yan, F. Patients with RT-PCR-confirmed COVID-19 and Normal Chest CT. Radiology, 2020, 295(2), E3-E3.
[http://dx.doi.org/10.1148/radiol.2020200702] [PMID: 32142398]
[42]
Udugama, B.; Kadhiresan, P.; Kozlowski, H.N.; Malekjahani, A.; Osborne, M.; Li, V.Y.C.; Chen, H.; Mubareka, S.; Gubbay, J.B.; Chan, W.C.W. Diagnosing COVID-19: the disease and tools for detection. ACS Nano, 2020, 14(4), 3822-3835.
[http://dx.doi.org/10.1021/acsnano.0c02624] [PMID: 32223179]
[43]
Alhazzani, W.; Møller, M.H.; Arabi, Y.M.; Loeb, M.; Gong, M.N.; Fan, E.; Oczkowski, S.; Levy, M.M.; Derde, L.; Dzierba, A.; Du, B.; Aboodi, M.; Wunsch, H.; Cecconi, M.; Koh, Y.; Chertow, D.S.; Maitland, K.; Alshamsi, F.; Belley-Cote, E.; Greco, M.; Laundy, M.; Morgan, J.S.; Kesecioglu, J.; McGeer, A.; Mermel, L.; Mammen, M.J.; Alexander, P.E.; Arrington, A.; Centofanti, J.E.; Citerio, G.; Baw, B.; Memish, Z.A.; Hammond, N.; Hayden, F.G.; Evans, L.; Rhodes, A. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med., 2020, 46(5), 854-887.
[http://dx.doi.org/10.1007/s00134-020-06022-5] [PMID: 32222812]
[44]
Rosales-Mendoza, S.; Márquez-Escobar, V.A.; González-Ortega, O.; Nieto-Gómez, R.; Arévalo-Villalobos, J.I. What does plant-based vaccine technology offer to the fight against COVID-19? Vaccines (Basel), 2020, 8(2), 183.
[http://dx.doi.org/10.3390/vaccines8020183] [PMID: 32295153]
[45]
Zhang, J.; Zeng, H.; Gu, J.; Li, H.; Zheng, L.; Zou, Q. Progress and prospects on vaccine development against SARS-CoV-2. Vaccines (Basel), 2020, 8(2), 153.
[http://dx.doi.org/10.3390/vaccines8020153] [PMID: 32235387]
[46]
Chen, W-H.; Strych, U.; Hotez, P.J.; Bottazzi, M.E. The SARS-CoV-2 vaccine pipeline: an overview. Curr. Trop. Med. Rep., 2020, 3, 1-4.
[http://dx.doi.org/10.1007/s40475-020-00201-6] [PMID: 32219057]
[47]
WHO; Draft landscape of COVID-19 candidate vaccines., Available at:. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines (Accessed date: Aug 11,2020.
[48]
Hodgson, J. The pandemic pipeline. Nat. Biotechnol., 2020, 38(5), 523-532.
[http://dx.doi.org/10.1038/d41587-020-00005-z] [PMID: 32203293]
[49]
Zhang, J.; Xie, B.; Hashimoto, K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav. Immun., 2020, 87, 59-73.
[http://dx.doi.org/10.1016/j.bbi.2020.04.046] [PMID: 32334062]
[50]
Moderna, Inc. Moderna announces positive interim phase 1 data for its mRNA vaccine (mRNA-1273) against novel coronavirus. Available at: . https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine/(Accessed date: Jun 3,2020.
[51]
Astrazeneca. AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford’s potential new vaccine . https://www.astrazeneca. com/media-centre/press-releases/2020/astrazeneca-advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-for-oxfords-potential-new-vaccine.html(Accessed date: Jun 3, 2020).
[52]
Tu, Y-F.; Chien, C-S.; Yarmishyn, A.A.; Lin, Y-Y.; Luo, Y-H.; Lin, Y-T.; Lai, W-Y.; Yang, D-M.; Chou, S-J.; Yang, Y-P.; Wang, M.L.; Chiou, S.H. A review of SARS-CoV-2 and the ongoing clinical trials. Int. J. Mol. Sci., 2020, 21(7), 2657.
[http://dx.doi.org/10.3390/ijms21072657] [PMID: 32290293]
[53]
bioworld. China approves first homegrown COVID-19 vaccine to enter clinical trials . https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials (Accessed date: Jun 3, 2020).
[54]
Zhu, F-C.; Li, Y-H.; Guan, X-H.; Hou, L-H.; Wang, W-J.; Li, J-X.; Wu, S-P.; Wang, B-S.; Wang, Z.; Wang, L.; Jia, S.Y.; Jiang, H.D.; Wang, L.; Jiang, T.; Hu, Y.; Gou, J.B.; Xu, S.B.; Xu, J.J.; Wang, X.W.; Wang, W.; Chen, W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet, 2020, 395(10240), 1845-1854.
[http://dx.doi.org/10.1016/S0140-6736(20)31208-3] [PMID: 32450106]
[55]
Lee, N.; McGeer, A. The starting line for COVID-19 vaccine development. Lancet, 2020, 395(10240), 1815-1816.
[http://dx.doi.org/10.1016/S0140-6736(20)31239-3] [PMID: 32473680]
[56]
McKee, D.L.; Sternberg, A.; Stange, U.; Laufer, S.; Naujokat, C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol. Res., 2020, •••157104859
[http://dx.doi.org/10.1016/j.phrs.2020.104859] [PMID: 32360480]
[57]
McCreary, E.K.; Pogue, J.M. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect. Dis.; 2020, 7(4) ofaa105.
[http://dx.doi.org/https://doi.org/10.1093/ofid/ofaa105] [PMID: 32284951]
[58]
Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020, 30(3), 269-271.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[59]
Holshue, M.L.; DeBolt, C.; Lindquist, S.; Lofy, K.H.; Wiesman, J.; Bruce, H.; Spitters, C.; Ericson, K.; Wilkerson, S.; Tural, A. Washington State 2019-NCoV Case Investigation Team; First Case Of, 2019, pp. 929-936.
[60]
Beigel, J.H.; Tomashek, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S. Remdesivir for the treatment of Covid-19-preliminary report. N. Engl. J. Med., 2020.
[http://dx.doi.org/10.1056/NEJMoa2007764]
[61]
Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Cao, B.; Wang, C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020, 395(10236), 1569-1578.
[http://dx.doi.org/10.1016/S0140-6736(20)31022-9] [PMID: 32423584]
[62]
Zhang, Y.; Xu, Q.; Sun, Z.; Zhou, L. Current targeted therapeutics against COVID-19: Based on first-line experience in China. Pharmacol. Res., 2020.157104854
[http://dx.doi.org/10.1016/j.phrs.2020.104854] [PMID: 32360585]
[63]
Chen, C.; Huang, J.; Cheng, Z.; Wu, J.; Chen, S.; Zhang, Y.; Chen, B.; Lu, M.; Luo, Y.; Zhang, J. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial; Med. Rxiv, 2020.
[http://dx.doi.org/10.1101/2020.03.17.20037432]
[64]
Lim, J.; Jeon, S.; Shin, H-Y.; Kim, M.J.; Seong, Y.M.; Lee, W.J.; Choe, K-W.; Kang, Y.M.; Lee, B.; Park, S-J. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of Lopinavir/Ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J. Korean Med. Sci., 2020, 35(6)e79
[http://dx.doi.org/10.3346/jkms.2020.35.e79] [PMID: 32056407]
[65]
Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Zhang, D.; Wang, C. A Trial of Lopinavir-Ritonavir in adults hospitalized with severe covid-19. N. Engl. J. Med., 2020, 382(19), 1787-1799.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[66]
Deng, L.; Li, C.; Zeng, Q.; Liu, X.; Li, X.; Zhang, H.; Hong, Z.; Xia, J. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J. Infect., 2020, 81(1), e1-e5.
[http://dx.doi.org/10.1016/j.jinf.2020.03.002] [PMID: 32171872]
[67]
Li, Y.; Xie, Z.; Lin, W.; Cai, W.; Wen, C.; Guan, Y.; Mo, X.; Wang, J.; Wang, Y.; Peng, P. An exploratory randomized, controlled study on the efficacy and safety of Lopinavir/Ritonavir or Arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI); Med. Rxiv, 2020.
[http://dx.doi.org/10.1101/2020.03.19.20038984]
[68]
Blaising, J.; Lévy, P.L.; Polyak, S.J.; Stanifer, M.; Boulant, S.; Pécheur, E-I. Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. Antiviral Res., 2013, 100(1), 215-219.
[http://dx.doi.org/10.1016/j.antiviral.2013.08.008] [PMID: 23981392]
[69]
Blaising, J.; Polyak, S.J.; Pécheur, E-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res., 2014, 107, 84-94.
[http://dx.doi.org/10.1016/j.antiviral.2014.04.006] [PMID: 24769245]
[70]
Wang, Z.; Yang, B.; Li, Q.; Wen, L.; Zhang, R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China Clin. Infect. Dis, 2020.
[http://dx.doi.org/10.1093/cid/ciaa272] [PMID: 32176772]
[71]
Arabi, Y.M.; Alothman, A.; Balkhy, H.H.; Al-Dawood, A.; AlJohani, S.; Al Harbi, S.; Kojan, S.; Al Jeraisy, M.; Deeb, A.M.; Assiri, A.M.; Al-Hameed, F.; AlSaedi, A.; Mandourah, Y.; Almekhlafi, G.A.; Sherbeeni, N.M.; Elzein, F.E.; Memon, J.; Taha, Y.; Almotairi, A.; Maghrabi, K.A.; Qushmaq, I.; Al Bshabshe, A.; Kharaba, A.; Shalhoub, S.; Jose, J.; Fowler, R.A.; Hayden, F.G.; Hussein, M.A. And the MIRACLE trial group. treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials, 2018, 19(1), 81.
[http://dx.doi.org/10.1186/s13063-017-2427-0] [PMID: 29382391]
[72]
Khalili, J.S.; Zhu, H.; Mak, N.S.A.; Yan, Y.; Zhu, Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J. Med. Virol., 2020, 92(7), 740-746.
[http://dx.doi.org/10.1002/jmv.25798] [PMID: 32227493]
[73]
Hung, I.F-N.; Lung, K-C.; Tso, E.Y-K.; Liu, R.; Chung, T.W-H.; Chu, M-Y.; Ng, Y-Y.; Lo, J.; Chan, J.; Tam, A.R.; Shum, H.P.; Chan, V.; Wu, A.K.; Sin, K.M.; Leung, W.S.; Law, W.L.; Lung, D.C.; Sin, S.; Yeung, P.; Yip, C.C.; Zhang, R.R.; Fung, A.Y.; Yan, E.Y.; Leung, K.H.; Ip, J.D.; Chu, A.W.; Chan, W.M.; Ng, A.C.; Lee, R.; Fung, K.; Yeung, A.; Wu, T.C.; Chan, J.W.; Yan, W.W.; Chan, W.M.; Chan, J.F.; Lie, A.K.; Tsang, O.T.; Cheng, V.C.; Que, T.L.; Lau, C.S.; Chan, K.H.; To, K.K.; Yuen, K.Y. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet, 2020, 395(10238), 1695-1704.
[http://dx.doi.org/10.1016/S0140-6736(20)31042-4] [PMID: 32401715]
[74]
Marano, G.; Vaglio, S.; Pupella, S.; Facco, G.; Catalano, L.; Liumbruno, G.M.; Grazzini, G. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus., 2016, 14(2), 152-157.
[http://dx.doi.org/10.2450/2015.0131-15] [PMID: 26674811]
[75]
Tian, X.; Li, C.; Huang, A.; Xia, S.; Lu, S.; Shi, Z.; Lu, L.; Jiang, S.; Yang, Z.; Wu, Y.; Ying, T. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect., 2020, 9(1), 382-385.
[http://dx.doi.org/10.1080/22221751.2020.1729069] [PMID: 32065055]
[76]
Garraud, O.; Heshmati, F.; Pozzetto, B.; Lefrere, F.; Girot, R.; Saillol, A.; Laperche, S. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus. Clin. Biol., 2016, 23(1), 39-44.
[http://dx.doi.org/10.1016/j.tracli.2015.12.003] [PMID: 26775794]
[77]
Rojas, M.; Rodríguez, Y.; Monsalve, D.M.; Acosta-Ampudia, Y.; Camacho, B.; Gallo, J.E.; Rojas-Villarraga, A.; Ramírez-Santana, C.; Díaz-Coronado, J.C.; Manrique, R.; Mantilla, R.D.; Shoenfeld, Y.; Anaya, J.M. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun. Rev., 2020, 19(7)102554
[http://dx.doi.org/10.1016/j.autrev.2020.102554] [PMID: 32380316]
[78]
Zhang, B.; Liu, S.; Tan, T.; Huang, W.; Dong, Y.; Chen, L.; Chen, Q.; Zhang, L.; Zhong, Q.; Zhang, X. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 Infection. Chest, 2020.
[http://dx.doi.org/10.1016/j.chest.2020.03.039] [PMID: 32243945]
[79]
Food and Drug Administration. Investigational COVID-19 Convalescent Plasma; Guidance for Industry, 2020, p. 12.
[80]
Barone, P.; DeSimone, R.A. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design. Transfusion (Paris), 2020.
[http://dx.doi.org/10.1111/trf.15843] [PMID: 32374891]
[81]
Yoshikawa, T.; Hill, T.; Li, K.; Peters, C.J.; Tseng, C-T.K. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J. Virol., 2009, 83(7), 3039-3048.
[http://dx.doi.org/10.1128/JVI.01792-08] [PMID: 19004938]
[82]
He, Y. National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia(Trial Version 7). Infect. Microb. Dis., 2020, 2(2), 48-54.
[http://dx.doi.org/10.1097/IM9.0000000000000022] [PMID: 32374891]
[83]
Ceribelli, A.; Motta, F.; De Santis, M.; Ansari, A.A.; Ridgway, W.M.; Gershwin, M.E.; Selmi, C. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J. Autoimmun., 2020, 109102442
[http://dx.doi.org/10.1016/j.jaut.2020.102442] [PMID: 32253068]
[84]
Cavalli, G.; De Luca, G.; Campochiaro, C.; Della-Torre, E.; Ripa, M.; Canetti, D.; Oltolini, C.; Castiglioni, B.; Tassan Din, C.; Boffini, N. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol., 2020, 2(6), e325-e331.
[http://dx.doi.org/10.1016/S2665-9913(20)30127-2] [PMID: 32501454]
[85]
Dong, L.; Hu, S.; Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther., 2020, 14(1), 58-60.
[http://dx.doi.org/10.5582/ddt.2020.01012] [PMID: 32147628]
[86]
Stebbing, J.; Phelan, A.; Griffin, I.; Tucker, C.; Oechsle, O.; Smith, D.; Richardson, P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis., 2020, 20(4), 400-402.
[http://dx.doi.org/10.1016/S1473-3099(20)30132-8] [PMID: 32113509]
[87]
Perricone, C.; Triggianese, P.; Bartoloni, E.; Cafaro, G.; Bonifacio, A.F.; Bursi, R.; Perricone, R.; Gerli, R. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J. Autoimmun., 2020, 111102468
[http://dx.doi.org/10.1016/j.jaut.2020.102468] [PMID: 32317220]
[88]
Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet, 2003, 361(9374), 2045-2046.
[http://dx.doi.org/10.1016/S0140-6736(03)13615-X] [PMID: 12814717]
[89]
Ministry of AYUSH. Available at: https://www.ayush.gov. in/ (Accessed date: Jun 30, . https://www.ayush.gov2020.
[90]
Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A.; Wagstaff, K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res., 2020, 178104787
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]
[91]
Schrezenmeier, E.; Dörner, T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol., 2020, 16(3), 155-166.
[http://dx.doi.org/10.1038/s41584-020-0372-x] [PMID: 32034323]
[92]
Gautret, P.; Lagier, J-C.; Parola, P.; Hoang, V.T.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V.E.; Tissot Dupont, H.; Honoré, S.; Colson, P.; Chabrière, E.; La Scola, B.; Rolain, J.M.; Brouqui, P.; Raoult, D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 2020, 56(1)105949
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[93]
Mehra, M.R.; Desai, S.S.; Ruschitzka, F.; Patel, A.N. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet, 2020.
[http://dx.doi.org/10.1016/S0140-6736(20)31180-6]
[94]
Mehra, M.R.; Ruschitzka, F.; Patel, A.N. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet, 2020, 395(10240), 1820.
[http://dx.doi.org/10.1016/S0140-6736(20)31324-6] [PMID: 32511943]
[95]
Khan, S.A.; Zia, K.; Ashraf, S.; Uddin, R.; Ul-Haq, Z. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J. Biomol. Struct. Dyn., 2020, 1-10.
[http://dx.doi.org/10.1080/07391102.2020.1751298] [PMID: 32238094]
[96]
Siddiqi, H.K.; Mehra, M.R. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J. Heart Lung Transplant., 2020, 39(5), 405-407.
[http://dx.doi.org/10.1016/j.healun.2020.03.012] [PMID: 32362390]
[97]
Fedson, D.S.; Opal, S.M.; Rordam, O.M. Hiding in plain sight: an approach to treating patients with severe COVID-19 Infection. MBio, 2020, 11(2), e00398-e20.
[http://dx.doi.org/10.1128/mBio.00398-20] [PMID: 32198163]
[98]
Center for Drug Evaluation and Research, Food and Drug Administration FDA Advises Patients on Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for COVID- 19. 2020.
[99]
Mehra, M.R.; Desai, S.S.; Kuy, S.; Henry, T.D.; Patel, A.N. Retraction: Cardiovascular disease, drug therapy, and mortality in Covid-19. N. Engl. J. Med., 2020, 382(26), 2582.
[http://dx.doi.org/10.1056/NEJMc2021225] [PMID: 32501665]

Rights & Permissions Print Cite
Article Metrics
83
2
Wayfinder Image
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy